Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Drops By 61.4%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 30,400 shares, a decline of 61.4% from the November 15th total of 78,800 shares. Based on an average daily volume of 1,400,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 7.5% of the company’s stock are sold short.

Avalon GloboCare Stock Up 17.7 %

Shares of NASDAQ ALBT traded up $0.74 during midday trading on Wednesday, reaching $4.93. 356,656 shares of the company’s stock traded hands, compared to its average volume of 513,735. The company has a market cap of $5.39 million, a price-to-earnings ratio of -0.23 and a beta of 0.27. The stock’s 50 day simple moving average is $3.08 and its 200-day simple moving average is $4.74. Avalon GloboCare has a one year low of $2.11 and a one year high of $21.60.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.